Condition
Thrombotic Thrombocytopenic Purpura, Acquired
Total Trials
5
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 4 (1)
Trial Status
Recruiting2
Unknown2
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07513948RecruitingPrimary
Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
NCT06928233Not ApplicableRecruitingPrimary
Association of TNFAIP3 With Immune-mediated TTP
NCT04720261Phase 2TerminatedPrimary
Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP
NCT05262881UnknownPrimary
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
NCT05135442Phase 4UnknownPrimary
Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP
Showing all 5 trials